Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) EBT (2019 - 2025)

Historic EBT for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to -$13.8 million.

  • Pulmonx's EBT rose 88.16% to -$13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$56.3 million, marking a year-over-year increase of 21.63%. This contributed to the annual value of -$55.9 million for FY2024, which is 726.37% up from last year.
  • As of Q3 2025, Pulmonx's EBT stood at -$13.8 million, which was up 88.16% from -$15.0 million recorded in Q2 2025.
  • Pulmonx's 5-year EBT high stood at -$10.1 million for Q3 2021, and its period low was -$16.1 million during Q2 2023.
  • Its 5-year average for EBT is -$14.0 million, with a median of -$14.0 million in 2022.
  • As far as peak fluctuations go, Pulmonx's EBT crashed by 16599.32% in 2021, and later soared by 1380.91% in 2024.
  • Pulmonx's EBT (Quarter) stood at -$12.9 million in 2021, then decreased by 9.2% to -$14.0 million in 2022, then grew by 2.83% to -$13.6 million in 2023, then increased by 3.69% to -$13.1 million in 2024, then fell by 5.27% to -$13.8 million in 2025.
  • Its EBT stands at -$13.8 million for Q3 2025, versus -$15.0 million for Q2 2025 and -$14.3 million for Q1 2025.